Wells Fargo Rates Zymeworks (ZYME) buy, $37 Price Target

Wells Fargo reaffirmed its buy rating on ZYME, setting a $37 price target, a 39.15% upside from the current price.

By EarningsIQ Research Desk · Published Jun 30, 2026, 11:02 AM EDT · Updated Jul 1, 2026, 2:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Wells Fargo rated Zymeworks Inc. ($ZYME) "buy" with a $37 price target on June 30, 2026.

Since the rating, $ZYME is up 2.2% after 1 week, down 13.1% after 1 month and down 4.2% to date (from the $26.14 close on Jun 30, 2026).

ZYME Zymeworks Inc.

$25.03 -5.97% year to date

Daily close · Oct 16, 2026

Key Points

Wells Fargo reiterated its buy rating for ZYME, maintaining a price target of $37 as of June 30, 2026.
Wells Fargo's $37 price target implies 39.15% upside from Zymeworks Inc.'s ($ZYME) current $26.59 share price.
ZYME shares traded at $26.59 on Tuesday, reflecting ongoing interest from institutional investors.
Recent insider buying activity includes purchases by executives Paul Schneider and Scott Platshon in April and May 2026.

Get $ZYME trade alerts by text

We text you when insiders, Congress or big funds trade $ZYME. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Zymeworks Inc. alert may contain errors. Disclosures

On June 30, 2026, Wells Fargo reiterated its buy rating on ZYME, setting a price target of $37. This reaffirmation reflects continued confidence in the company's outlook.

Analyst rating track record

Wells Fargo vs. the S&P 500

YTD return -12.25% hypothetical

All-time return +10.48% S&P 500 +34.84%

vs. S&P 500 -24.36% behind the index

Hypothetical returns from Wells Fargo's disclosed trades, not real profit or advice. How we model this.

Other Institutional Activity in ZYME

ECOR1 Capital, LLC maintained its substantial stake in ZYME with 22,970,388 shares valued at approximately $575.2 million. Rubric Capital Management LP increased its holdings by 1,250,000 shares, bringing its total to 7,000,000 shares worth about $175.3 million, marking a 21.7% increase. BlackRock, Inc. slightly reduced its position by 41,660 shares, ending with 4,553,888 shares valued at $114.0 million, a decrease of 0.9%. BVF Inc/IL also trimmed its stake by 204,499 shares, now holding 3,734,142 shares worth roughly $93.5 million, a 5.2% reduction. Meanwhile, Perceptive Advisors LLC boosted its holdings by 248,228 shares to 3,510,078 shares, valued at approximately $87.9 million, a 7.6% increase.

Insider Buying and Selling at Zymeworks Inc.

Recent insider activity at ZYME includes significant buying by executives. On May 13, 2026, Paul Schneider, EVP and General Counsel, purchased 178,000 shares, followed by an additional 119,000 shares on the same day. Earlier, on April 9, 2026, Scott Platshon, EVP and Chief Business Officer, acquired 76,000 shares and then 47,000 more, while Adam Schayowitz, EVP and Head of Research & Development, bought 47,000 shares, followed by 76,000 shares later that day.

Analysts Set New Price Targets

On June 30, 2026, Wells Fargo maintained its buy rating for ZYME with a $37 price target. Earlier, on May 8, 2026, Wells Fargo reiterated a buy rating with a $34 target. Other firms like Evercore ISI Group, HC Wainwright & Co., Stifel, and Leerink Partners have maintained buy ratings with targets ranging from $46 to $58. Truist Securities initiated coverage with a buy rating and a $40 target on December 17, 2025.

Bottom Line

Wells Fargo's reaffirmation of its buy rating on ZYME, along with a $37 price target, indicates a positive outlook for the company. Institutional investors are actively managing their positions, with some increasing and others reducing their stakes. Recent insider buying activity suggests confidence from company executives. As always, it's important to remember that analyst ratings are just one piece of the puzzle, and investors should consider a range of factors when evaluating a stock.

12-month forecast